Hematology

News

$Adding Daratumumab to Carfilzomib, Dexamethasone Improves PFS In Relapsed/Refractory Multiple Myeloma$

Adding Daratumumab to Carfilzomib, Dexamethasone Improves PFS In Relapsed/Refractory Multiple Myeloma

December 10, 2019

Apixaban Linked to Large Reductions in Major Bleeding, Recurrent VTE in Active Cancer

December 07, 2019 – Maggie L. Shaw

Fractures in Patients With MM Negatively Impact Survival, Study Says

December 06, 2019 – AJMC Staff

FDA Approves Novel Sickle Cell Disease Treatment Voxelotor

November 25, 2019 – Allison Inserro

Journals

Policy

January 18, 2019

Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia

July 11, 2018 – Kelly Fust, MS; Anju Parthan, PhD; Xiaoyan Li, PhD; Anjali Sharma, MD; Xinke Zhang, MS; Marco Campioni, PhD; Junji Lin, PhD, MS; Xuena Wang, PhD; Richard Zur, PhD; Karynsa Cetin, MPH; Melissa Eisen, MD; and David Chandler, PhD

The Importance of Teamwork in Oncology Care Transitions

February 28, 2018 – Surabhi Dangi-Garimella, PhD

Conferences

Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg

April 06, 2019 – Mary Caffrey

NCCN Panel Digs Into Reality of CAR T-Cell Reimbursement

March 21, 2019 – Mary Caffrey

NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward

December 18, 2018 – Jaime Rosenberg

Multimedia

Final Thoughts on Approach to Multiple Myeloma Treatment

Biochemical Versus Symptomatic Relapse Treatment Choices in MM

Study Summaries

Study Summary: Amrubicin, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

October 23, 2018

Study Summary: Response and Progression-Free Survival at 18 Months With Lenalidomide and Dexamethasone

October 23, 2018

Study Summary: Once-Weekly Versus Twice-Weekly Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma: ARROW Interim Analysis

October 23, 2018

Study Summary: Ixazomib, Cyclophosphamide, and Dexamethasone for Previously Untreated Symptomatic Multiple Myeloma

October 23, 2018

Study Summary: Cardiovascular Safety Profile of Carfilzomib in Multiple Myeloma Clinical Trials

October 18, 2018

Study Summary: Carfilzomib + Dexamethasone Versus Bortezomib (SC or IV) + Dexamethasone in Relapsed or Refractory Multiple Myeloma (ENDEAVOR Secondary Analysis)

October 18, 2018

Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma

October 18, 2018

Study Summary: The Role of Race and Ethnicity in Disease and Outcome Disparities in Multiple Myeloma

October 18, 2018

Hematology

News

Journals

Conferences

Multimedia

Study Summaries

Sign In